Humana Inc. $HUM Shares Acquired by Pzena Investment Management LLC

Pzena Investment Management LLC lifted its position in Humana Inc. (NYSE:HUM) by 34.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,470,982 shares of the insurance provider’s stock after buying an additional 1,398,774 shares during the quarter. Humana makes up 3.1% of Pzena Investment Management LLC’s investment portfolio, making the stock its 8th largest holding. Pzena Investment Management LLC owned approximately 4.56% of Humana worth $948,614,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HUM. Revolve Wealth Partners LLC acquired a new stake in shares of Humana during the fourth quarter worth about $202,000. Woodline Partners LP grew its holdings in shares of Humana by 460.0% in the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock valued at $2,697,000 after purchasing an additional 8,372 shares in the last quarter. Sivia Capital Partners LLC increased its stake in Humana by 53.7% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock worth $316,000 after buying an additional 452 shares during the period. Cresset Asset Management LLC lifted its holdings in Humana by 10.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock worth $581,000 after buying an additional 222 shares in the last quarter. Finally, WINTON GROUP Ltd boosted its position in Humana by 58.5% in the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock valued at $582,000 after buying an additional 879 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of HUM stock opened at $409.92 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The firm has a fifty day moving average price of $314.71 and a 200 day moving average price of $248.64. The company has a market cap of $49.22 billion, a P/E ratio of 43.84, a PEG ratio of 2.26 and a beta of 0.71. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $414.82.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The company had revenue of $39.65 billion for the quarter, compared to analysts’ expectations of $39.37 billion. During the same period last year, the firm earned $11.58 earnings per share. Humana’s quarterly revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. Sell-side analysts predict that Humana Inc. will post 9.04 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Humana’s dividend payout ratio (DPR) is 37.86%.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on Humana from $214.00 to $316.00 and gave the stock a “neutral” rating in a research report on Monday, June 8th. Wells Fargo & Company lowered Humana from a “cautious” rating to a “reduce” rating in a report on Wednesday, May 20th. Leerink Partners boosted their target price on Humana from $185.00 to $255.00 and gave the stock a “market perform” rating in a research note on Thursday, April 30th. Seaport Research Partners downgraded Humana to a “neutral” rating in a report on Wednesday, May 20th. Finally, Guggenheim increased their price target on Humana from $252.00 to $269.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus price target of $293.09.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.